MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer

Sophie Leboulleux; Daniele Benisvy; David Taieb; Marie Attard; Claire Bournaud; Marie Terroir-Cassou-Mounat; Ludovic Lacroix; Nadege Anizan; Aurelie Schiazza; Marie Eve Garcia; Abir Al Ghuzlan; Livia Lamartina; Martin Schlumberger; Yann Godbert; Isabelle Borget

doi:10.1089/thy.2023.0240

MERAIODE: A Phase II Redifferentiation Trial with Trametinib and ¹³¹I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer

Sophie Leboulleux, Daniele Benisvy, David Taieb, Marie Attard, Claire Bournaud, Marie Terroir-Cassou-Mounat, Ludovic Lacroix, Nadege Anizan, Aurelie Schiazza, Marie Eve Garcia, Abir Al Ghuzlan, Livia Lamartina, Martin Schlumberger, Yann Godbert, Isabelle Borget

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

12 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	1124-1129
Nombre de pages	6
journal	Thyroid
Volume	33
Numéro de publication	9
Les DOIs	https://doi.org/10.1089/thy.2023.0240
état	Publié - 1 sept. 2023

Accès au document

10.1089/thy.2023.0240

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Leboulleux, S., Benisvy, D., Taieb, D., Attard, M., Bournaud, C., Terroir-Cassou-Mounat, M., Lacroix, L., Anizan, N., Schiazza, A., Garcia, M. E., Ghuzlan, A. A., Lamartina, L., Schlumberger, M., Godbert, Y., & Borget, I. (2023). MERAIODE: A Phase II Redifferentiation Trial with Trametinib and ¹³¹I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer. Thyroid, 33(9), 1124-1129. https://doi.org/10.1089/thy.2023.0240

@article{d8817afd230d4a88bdfc9428624cd2af,

title = "MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer",

author = "Sophie Leboulleux and Daniele Benisvy and David Taieb and Marie Attard and Claire Bournaud and Marie Terroir-Cassou-Mounat and Ludovic Lacroix and Nadege Anizan and Aurelie Schiazza and Garcia, {Marie Eve} and Ghuzlan, {Abir Al} and Livia Lamartina and Martin Schlumberger and Yann Godbert and Isabelle Borget",

note = "Funding Information: MERAIODE was financed by the French Ministry of Health, through the National Institute for Cancer (INCa, PHRC2015). Trametinib was provided by Novartis, and rhTSH was provided by Sanofi Genzyme. These companies did not participate in any aspect of the study design, data accrual, data analysis, or manuscript preparation and submission. The authors assume responsibility for the accuracy and completeness of the data and analyses (NCT 03244956). ",

year = "2023",

month = sep,

day = "1",

doi = "10.1089/thy.2023.0240",

language = "English",

volume = "33",

pages = "1124--1129",

journal = "Thyroid",

issn = "1050-7256",

number = "9",

}

Leboulleux, S, Benisvy, D, Taieb, D, Attard, M, Bournaud, C, Terroir-Cassou-Mounat, M, Lacroix, L, Anizan, N, Schiazza, A, Garcia, ME, Ghuzlan, AA, Lamartina, L, Schlumberger, M, Godbert, Y & Borget, I 2023, 'MERAIODE: A Phase II Redifferentiation Trial with Trametinib and ¹³¹I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer', Thyroid, VOL. 33, Numéro 9, p. 1124-1129. https://doi.org/10.1089/thy.2023.0240

TY - JOUR

T1 - MERAIODE

T2 - A Phase II Redifferentiation Trial with Trametinib and 131I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer

AU - Leboulleux, Sophie

AU - Benisvy, Daniele

AU - Taieb, David

AU - Attard, Marie

AU - Bournaud, Claire

AU - Terroir-Cassou-Mounat, Marie

AU - Lacroix, Ludovic

AU - Anizan, Nadege

AU - Schiazza, Aurelie

AU - Garcia, Marie Eve

AU - Ghuzlan, Abir Al

AU - Lamartina, Livia

AU - Schlumberger, Martin

AU - Godbert, Yann

AU - Borget, Isabelle

N1 - Funding Information: MERAIODE was financed by the French Ministry of Health, through the National Institute for Cancer (INCa, PHRC2015). Trametinib was provided by Novartis, and rhTSH was provided by Sanofi Genzyme. These companies did not participate in any aspect of the study design, data accrual, data analysis, or manuscript preparation and submission. The authors assume responsibility for the accuracy and completeness of the data and analyses (NCT 03244956).

PY - 2023/9/1

Y1 - 2023/9/1

UR - http://www.scopus.com/inward/record.url?scp=85167425241&partnerID=8YFLogxK

U2 - 10.1089/thy.2023.0240

DO - 10.1089/thy.2023.0240

M3 - Article

C2 - 37350119

AN - SCOPUS:85167425241

SN - 1050-7256

VL - 33

SP - 1124

EP - 1129

JO - Thyroid

JF - Thyroid

IS - 9

ER -